These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 17589337)
1. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Jahng AW; Tran T; Bui L; Joyner JL Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337 [TBL] [Abstract][Full Text] [Related]
2. Is isoniazid safe for liver transplant candidates with latent tuberculosis? Stucchi RS; Boin IF; Angerami RN; Zanaga L; Ataide EC; Udo EY Transplant Proc; 2012 Oct; 44(8):2406-10. PubMed ID: 23026607 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Singh N; Wagener MM; Gayowski T Transplantation; 2002 Sep; 74(6):892-5. PubMed ID: 12364876 [TBL] [Abstract][Full Text] [Related]
4. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199 [TBL] [Abstract][Full Text] [Related]
6. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Vikrant S; Agarwal SK; Gupta S; Bhowmik D; Tiwari SC; Dash SC; Guleria S; Mehta SN Transpl Infect Dis; 2005; 7(3-4):99-108. PubMed ID: 16390397 [TBL] [Abstract][Full Text] [Related]
7. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Wu SS; Chao CS; Vargas JH; Sharp HL; MartÃn MG; McDiarmid SV; Sinatra FR; Ament ME Transplantation; 2007 Jul; 84(2):173-9. PubMed ID: 17667808 [TBL] [Abstract][Full Text] [Related]
8. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Ziakas PD; Mylonakis E Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936 [TBL] [Abstract][Full Text] [Related]
9. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Spyridis NP; Spyridis PG; Gelesme A; Sypsa V; Valianatou M; Metsou F; Gourgiotis D; Tsolia MN Clin Infect Dis; 2007 Sep; 45(6):715-22. PubMed ID: 17712755 [TBL] [Abstract][Full Text] [Related]
10. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis. Fresard I; Bridevaux PO; Rochat T; Janssens JP Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452 [TBL] [Abstract][Full Text] [Related]
11. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Priest DH; Vossel LF; Sherfy EA; Hoy DP; Haley CA Clin Infect Dis; 2004 Dec; 39(12):1764-71. PubMed ID: 15578397 [TBL] [Abstract][Full Text] [Related]
12. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. Young H; Wessolossky M; Ellis J; Kaminski M; Daly JS Clin Infect Dis; 2009 Aug; 49(3):424-7. PubMed ID: 19548835 [TBL] [Abstract][Full Text] [Related]
13. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Hanta I; Ozbek S; Kuleci S; Sert M; Kocabas A Clin Rheumatol; 2007 Nov; 26(11):1867-70. PubMed ID: 17332973 [TBL] [Abstract][Full Text] [Related]
14. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943 [TBL] [Abstract][Full Text] [Related]
15. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686 [TBL] [Abstract][Full Text] [Related]
16. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area. Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606 [TBL] [Abstract][Full Text] [Related]
17. Liver transplantation without isoniazid prophylaxis for recipients with a history of tuberculosis. Nagai S; Fujimoto Y; Taira K; Egawa H; Takada Y; Kiuchi T; Tanaka K Clin Transplant; 2007; 21(2):229-34. PubMed ID: 17425750 [TBL] [Abstract][Full Text] [Related]
18. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C; Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615 [TBL] [Abstract][Full Text] [Related]
19. Various clinical presentations of tuberculosis in heart transplant recipients. Chou NK; Liu LT; Ko WJ; Hsu RB; Chen YS; Yu HY; Chi NH; Chang SC; Wang SS Transplant Proc; 2004 Oct; 36(8):2396-8. PubMed ID: 15561261 [TBL] [Abstract][Full Text] [Related]
20. Tuberculosis in children and its management. Abernathy RS Semin Respir Infect; 1989 Sep; 4(3):232-42. PubMed ID: 2688006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]